Dr. Rosana Kapeller is Chief Scientific Officer of Nimbus and holds responsibility for advancing the company’s programs from discovery to early human proof-of-concept. She has spearheaded Nimbus’ pioneering experiment in virtual distributed drug discovery, an innovative and cost-effective approach to R&D and has been instrumental in bringing the company from a discovery platform to a product-focused therapeutic development platform. Rosana’s scientific vision and leadership contributed to the sale of the company’s lead program targeting ACC for NASH to Gilead for up to $1.2 billion. She brings to Nimbus over 20 years of leadership and start-up experience. As co-founder and Vice President of Research at Aileron Therapeutics, Rosana helped the company raise $60 million in venture funding. Before that, she spent nearly 10 years at Millennium Pharmaceuticals, where she rose to the role of Director of the Department of Molecular and Cellular Biology. Over the course of her career, Rosana has been widely published and is named on 50 issued patents. She was recognized as one of the “Top 20 Women to Watch” by Mass High Tech in 2012, and was selected as the Rising Star Entrepreneur of 2016 by the New England Venture Capital Association (NEVCA). Rosana earned her M.D. from Rio de Janeiro State University in Brazil and her Ph.D. from Tufts University Medical School. She conducted her postdoctoral research work at the Dana-Farber Cancer Institute, where she was named a David Abraham Fellow in Pediatric Oncology.